Figure 4.

Development of systolic blood pressure of WKY rats (a–c) and SHRs (d–f) treated with vehicle or rofecoxib (10 mg kg⁻¹ d⁻¹) for 4 weeks during low salt intake (0.02%, wt wt⁻¹) (a, d), normal salt intake (0.6%, wt wt⁻¹) (b, e) or high salt intake (8%, wt wt⁻¹) (c, f). Data represent the mean±s.e.mean of n=8 rats. Asterisk indicates significance of control rats to rofecoxib treated rats.